同时管理缺血性priapism:一个12年的基于人口的分析从一个大型的美国数据库
Leslie Claire Licari1,2, Eugenio Bologna1,2, Francesco Ditonno1
1Department of Urology, Rush University, Chicago, Illinois, USA.
Andrology
|August 14, 2024
概括
大多数缺血性 priapism 病例都是用药物治疗来治疗的,很少需要阴茎假体植入 (PPI). 年龄和并发症预测勃起功能障碍 (ED) 和需要PPI.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
背景情况:
- 缺血性 priapism 是一种带有持续勃起的泌尿器科紧急情况.
- 管理策略各不相同,但对患者特征的大规模数据有限.
研究的目的:
- 分析美国当代缺血性青症的管理.
- 探索患者的人口统计学,临床特征和勃起功能障碍 (ED) 和阴茎假体植入 (PPI) 的预测因素.
主要方法:
- 对PearlDiver Mariner数据库 (2010-2021) 的回顾性分析.
- 包括被诊断患有缺血性priapism的成年男性.
- 多变量逻辑回归分析了de novoED和PPI的预测因素.
主要成果:
- 93%的患者接受了医疗管理;7%接受了手术干预 (阴茎分流手术,PPI或两者兼而有之).
- 在16.57%的患者中,医疗管理导致了新的ED.
- 老年,代谢疾病,神经性疾病,盆腔恶性瘤和多次青症预测了新发性ED和PPI.
结论:
- 医学治疗是缺血性priapism的主要治疗方法.
- 阴茎假肢植入 (PPI) 不常见 (<3%),而充气假肢更受青.
- 年龄,并发症和反复发生的priapism是ED和PPI的关键预测因素.
更多相关视频
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
600
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138